Biogen stock price target lowered to $144 at Morgan Stanley

Published 31/07/2025, 21:02
Biogen stock price target lowered to $144 at Morgan Stanley

Investing.com - Morgan Stanley (NYSE:MS) has reduced its price target on Biogen (NASDAQ:BIIB) to $144.00 from $146.00 while maintaining an Equalweight rating on the stock. Currently trading at $127.99, with a P/E ratio of 12.55, InvestingPro analysis suggests the stock is undervalued.

The adjustment follows Biogen’s second-quarter performance, which exceeded expectations and prompted the company to raise its guidance. The company maintains strong fundamentals with a 75.65% gross profit margin and robust free cash flow yield.

According to Morgan Stanley, Leqembi’s worldwide sales beat was driven by continued momentum in Japan, while Skyclarys sales were in line with expectations.

The firm noted that Biogen’s legacy multiple sclerosis franchise outperformed during the quarter.

Morgan Stanley identified the FDA action on Leqembi SQ maintenance, with a PDUFA date of August 31, and potential lateral Alzheimer’s prevention data from Eli Lilly (NYSE:LLY)’s Kisunla as the next catalysts for the stock.

In other recent news, Biogen reported impressive financial results for the second quarter of 2025, surpassing earnings expectations. The company achieved an earnings per share (EPS) of $5.47, significantly exceeding the forecasted $3.99. Revenue also surpassed predictions, reaching $2.65 billion, higher than both Oppenheimer’s estimate of $2.29 billion and the consensus estimate of $2.32 billion. This marked a 12.07% revenue surprise. As a result of these strong financials, Biogen has updated its fiscal year 2025 guidance, projecting flat revenues at constant currency compared to fiscal year 2024. Oppenheimer has reiterated its Outperform rating on Biogen with a price target of $205.00. These developments reflect positively on the company’s financial health and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.